• Takeshi Kodaira, Nobukazu Fuwa, Kazuhisa Furutani, Hiroyuki Tachibana, and Takuya Yamazaki.
• Department of Therapeutic Radiation Oncology, Aichi Cancer Center, Chikusa-ku, 464-8681 Nagoya, Aichi, Japan. 109103@aichi-cc.jp
• Jpn. J. Clin. Oncol. 2005 Apr 1; 35 (4): 173-6.

ObjectiveWe planned a phase I study of radiotherapy combined with weekly docetaxel for elderly patients or patients with complications to find out the optimal dose.MethodsFive consecutive weekly administrations of docetaxel were accompanied by radiotherapy for patients diagnosed with squamous cell carcinoma of the head and neck. The starting dose of docetaxel was 10 mg/m(2) with escalation at 2 mg/m(2) per step.ResultsFifteen patients were enrolled in this trial. The maximal tolerated dose was 14 mg/m(2), so the recommended dose was determined as 12 mg/m(2). Hematological toxicity was sufficiently weak. Common dose-limiting toxicity was stomatitis within the radiation field.ConclusionsThis protocol was thought to be practical for elderly patients or those with medical complications.

28 keywords...

hide…